Advertisement

Corpus Uteri Carcinoma

  • J. L. Benedet
  • T. G. Ehlen
  • E. Kovacs
  • H. Ludwig
Part of the UICC International Union Against Cancer / Union Internationale Contre le Cancer book series (UICCI)

Abstract

In many countries, carcinoma of the corpus uteri (endometrial carcinoma) has now surpassed cervical carcinoma as the most common form of malignancy affecting the female genital tract. This has occurred as the result of two factors. Firstly, the effective population-based cervical carcinoma screening programs have effectively identified the preclinical phases of this disease with a subsequent reduction in its incidence and mortality rates. Second, the increased life-expectancy in many countries today has, in turn, led to an increased number of patients being diagnosed with endometrial carcinoma, which is predominantly a disease of post-menopausal women. Endometrial carcinoma most often presents as postmenopausal bleeding, which results in women presenting promptly for investigation of this complaint. The majority of endometrial carcinomas are diagnosed as stage I lesions [37]. Nonetheless, this condition has the potential to behave in an aggressive fashion, resulting in recurrence and ultimately death. The identification of prognostic factors has been the primary focus of the research on this condition in the past 20 years. Prognostic factors in stage I and II and in stage III and IV disease are shown in Tables 1 and 2, respectively.

Keywords

Endometrial Cancer Endometrial Carcinoma Radical Hysterectomy Myometrial Invasion Endometrial Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aalders J, Abeler V, Kolstad P et al (1980) Postoperative exteraal irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56: 419–427PubMedGoogle Scholar
  2. 2.
    Abeler VM, Kjorstad KE (1990) Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 39: 266–271PubMedCrossRefGoogle Scholar
  3. 3.
    Abeler VM, Kjorstad KE (1991) Endometrial adenocarcinoma in Norway. Cancer 67: 3093 - 3103PubMedCrossRefGoogle Scholar
  4. 4.
    Ambros RA, Kurman RJ (1992) Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 45: 235–239PubMedCrossRefGoogle Scholar
  5. 5.
    Berchuck A, Rodriguez G, Kinney RB et al (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15–21PubMedGoogle Scholar
  6. 6.
    Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10–17PubMedCrossRefGoogle Scholar
  7. 7.
    Boronow RC, Morrow CP, Creasman WT et al (1984) Surgical staging in endometrial cancer: clinical-pathological findings of a prospective study. Obstet Gynecol 63: 825–832PubMedGoogle Scholar
  8. 8.
    Britton LC, Wilson TO, Gaffey TA et al (1989) Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 34: 317–322PubMedCrossRefGoogle Scholar
  9. 9.
    Christopherson W, Alberhasky RC, Connelly PJ (1982) Carcinoma of the endometrium. I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 49: 1511–1523PubMedCrossRefGoogle Scholar
  10. 10.
    Connelly PJ, Alberhasky RC, Christopherson WM (1982) Carcinoma of the endometrium. III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 59: 569–575PubMedGoogle Scholar
  11. 11.
    Creasman WT (1993) Prognostic significance of hormone receptors in endometrial cancer. Cancer 71: 1467–1470PubMedCrossRefGoogle Scholar
  12. 12.
    Creasman WT, Morrow CP, Bundy BN et al (1987) Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 60: 2035–2041PubMedCrossRefGoogle Scholar
  13. 13.
    DeMuelenaere GF (1975) Prognostic factors in endometrial carcinoma. S Afr Med J 49: 1695Google Scholar
  14. 14.
    DiSaia PJ, Creasman WT, Boronow RC et al (1985) Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol 151: 1009–1015PubMedGoogle Scholar
  15. 15.
    FIGO (1990) Changes in gynecologic cancer staging by the International Federation of Gyne¬cology and Obstetrics. Am J Obstet Gynecol 162: 610–611Google Scholar
  16. 16.
    Friberg L, Noren H (1993) Prognostic value of steroid hormone receptors for 5-year survival in stage II endometrial cancer. Cancer 71: 3570–3574PubMedCrossRefGoogle Scholar
  17. 17.
    Fujimoto I, Shimizu Y, Hirai Y et al (1993) Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol 48: 196–202PubMedCrossRefGoogle Scholar
  18. 18.
    Gal D, Recio FO, Zamurovic D et al (1991) Lymphvascular space involvement - a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 42: 142–145PubMedCrossRefGoogle Scholar
  19. 19.
    Gallion HH, Van Nagell JR, Powell DF et al (1989) Stage I serous papillary carcinoma of the endometrium. Cancer 63: 2224–2228PubMedCrossRefGoogle Scholar
  20. 20.
    Genest P, Drouin P, Erig L Et Al (1987) Prognostic factors in early carcinoma of the endome¬trium. Am J Clin Oncol 10: 71–77PubMedCrossRefGoogle Scholar
  21. 21.
    Greven KM, Lanciano RM, Corn B Et Al (1993) Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 71: 3697–3702Google Scholar
  22. 22.
    Hendrickson M, Ross J, Eifel P et al (1982) Uterine papillary serious carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6: 93–108PubMedCrossRefGoogle Scholar
  23. 23.
    Hetzel DJ, Wilson TO, Keeney GL et al (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179–185PubMedCrossRefGoogle Scholar
  24. 24.
    Iversen OE, Utaaker E, Skaarland E (1988) DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 67: 531–537PubMedCrossRefGoogle Scholar
  25. 25.
    Kadar N, Homesley HD, Malfetano JH (1992) Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 46: 145–149PubMedCrossRefGoogle Scholar
  26. 26.
    Kadar N, Malfetano JH, Homesley HD (1992) Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 80: 655–659PubMedGoogle Scholar
  27. 27.
    Kadar N, Malfetano JH, Homesley HD (1993) Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 50: 281–286PubMedCrossRefGoogle Scholar
  28. 28.
    Kleine W, Maier T, Geyer H et al (1990) Estrogen and progesterone receptors in endometrial cancer and their prognostic value. Gynecol Oncol 38: 59–65PubMedCrossRefGoogle Scholar
  29. 29.
    Lewis BV, Stall worthy JA, Cowdell R (1970) Adenocarcinoma of the body of the uterus. J Obstet Gynaecol Br Commonw 77: 343–348PubMedCrossRefGoogle Scholar
  30. 30.
    Lurain JR, Rice BL, Rademaker AW (1991) Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 78: 63–69PubMedGoogle Scholar
  31. 31.
    Lutz MH, Underwood PB, Kreutner A et al (1978) Endometrial carcinoma: a new method of classification of therapeutic and prognostic significance. Gynecol Oncol 6: 83–94PubMedCrossRefGoogle Scholar
  32. 32.
    Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40: 55–65PubMedCrossRefGoogle Scholar
  33. 33.
    Rutledge F (1974) The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol 2: 331–347PubMedCrossRefGoogle Scholar
  34. 34.
    Sherman ME, Bitterman P, Rosenshein NB et al (1992) Uterine serous carcinoma: a morpho¬logically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 16: 600–610PubMedCrossRefGoogle Scholar
  35. 35.
    Symonds DA (1990) Prognostic value of pathologic features and DNA analysis in endometrial carcinoma. Gynecol Oncol 39: 272–276PubMedCrossRefGoogle Scholar
  36. 36.
    Turner DA, Gershenson DM, Atkinson N et al (1989) The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 74: 775–780PubMedGoogle Scholar
  37. 37.
    UICC International Union Against Cancer (1992) TNM classification of malignant tumours, 4th edn, 2nd rev. Springer, Berlin Heidelberg New YorkGoogle Scholar
  38. 38.
    Wilson TO, Podratz KC, Gaffey TA et al (1990) Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 162: 418–426PubMedGoogle Scholar

Copyright information

© International Union Against Cancer, Geneva 1995

Authors and Affiliations

  • J. L. Benedet
  • T. G. Ehlen
  • E. Kovacs
  • H. Ludwig

There are no affiliations available

Personalised recommendations